---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-000154"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:27:11.933268+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCryst prelim 2022 ORLADEYO rev $251.6M (+105% YoY); FY23 guide ≥$320M; BCX10013 data positive

## Summary
- Prelim 2022 ORLADEYO net rev $251.6M (+105% YoY); Q4 rev $70.7M (+53% YoY).
- FY2023 ORLADEYO net rev guidance no less than $320M; company expects peak sales of $1B.
- Phase1 data for BCX10013 (oral Factor D inhibitor): >97% AP suppression at 110 mg single dose, safe/well-tolerated.
- Advancing BCX10013 into patient studies mid-2023 for PNH and IgAN; expanding complement platform to C2 targets.

## SEC filing metadata
- accession: 0001171843-23-000154
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184323000154/0001171843-23-000154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184323000154/f8k_010923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-000154
- JSON: https://secwatch.observer/filing/0001171843-23-000154.json
- Plain text: https://secwatch.observer/filing/0001171843-23-000154.txt

## Key facts
- Earnings Releases
  BIOCRYST PHARMACEUTICALS INC reported the fourth quarter and full year ended December 31, 2022 results: revenue $70.7 million. Guidance raised.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $70.7 million
  - Guidance: raised
  - Result: preliminary results
  source text: for many years to come,” said Jon Stonehouse, president and chief executive officer of BioCryst. Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2022 was $70.7 million (+53 percent y-o-y). Preliminary, unaudited ORLADEYO net revenue for full year 2022 was $251.6 million (+105 percent y-o-y). Fourth Quarter and Full Year 2022 ORLADEYO Revenue
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184323000154/0001171843-23-000154-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.